|
1
|
Tsai WL and Chung RT: Viral
hepatocarcinogenesis. Oncogene. 29:2309–2324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schütte K, Bornschein J and Malfertheiner
P: Hepatocellular carcinoma - epidemiological trends and risk
factors. Dig Dis. 27:80–92. 2009.PubMed/NCBI
|
|
3
|
Bikfalvi A: Significance of angiogenesis
in tumour progression and metastasis. Eur J Cancer. 31A:1101–1104.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ingber D, Fujita T, Kishimoto S, Sudo K,
Kanamaru T, Brem H and Folkman J: Synthetic analogues of fumagillin
that inhibit angiogenesis and suppress tumour growth. Nature.
348:555–557. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folkman J and Shing Y: Angiogenesis. J
Biol Chem. 267:10931–10934. 1992.
|
|
7
|
Pluda JM: Tumor-associated angiogenesis:
mechanisms, clinical implications, and therapeutic strategies.
Semin Oncol. 24:203–218. 1997.PubMed/NCBI
|
|
8
|
Folkman J: Anti-angiogenesis: new concept
for therapy of solid tumors. Ann Surg. 175:409–416. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brem H and Folkman J: Inhibition of tumor
angiogenesis mediated by cartilage. J Exp Med. 141:427–439. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Voest EE: Inhibitors of angiogenesis in a
clinical perspective. Anticancer Drugs. 7:723–727. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jung YD, Ahmad SA, Liu W, Reinmuth N,
Parikh A, Stoeltzing O, Fan F and Ellis LM: The role of the
microenvironment and intercellular cross-talk in tumor
angiogenesis. Semin Cancer Biol. 12:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krebs LT, Xue Y, Norton CR, et al: Notch
signaling is essential for vascular morphogenesis in mice. Genes
Dev. 14:1343–1352. 2000.PubMed/NCBI
|
|
13
|
Krebs LT, Shutter JR, Tanigaki K, Honio T,
Stark KL and Gridley T: Haploinsufficient lethality and formation
of arteriovenous malformations in Notch pathway mutants. Genes Dev.
18:2469–2473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xue Y, Gao X, Lindsell CE, et al:
Embryonic lethality and vascular defects in mice lacking the Notch
ligand Jagged1. Hum Mol Genet. 8:723–730. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo S, Liu M and Gonzalez-Perez RR: Role
of Notch and its oncogenic signaling crosstalk in breast cancer.
Biochim Biophys Acta. 1815:197–213. 2011.PubMed/NCBI
|
|
17
|
Li JL and Harris AL: Notch signaling from
tumor cells: a new mechanism of angiogenesis. Cancer Cell. 8:1–3.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taylor KL, Henderson AM and Hughes CC:
Notch activation during endothelial cell network formation in vitro
targets the basic HLH transcription factor HESR-1 and downregulates
VEGFR-2/KDR expression. Microvasc Res. 64:372–383. 2002. View Article : Google Scholar
|
|
19
|
Williams CK, Li JL, Murga M, Harris AL and
Tosato G: Upregulation of the Notch ligand Delta-like 4 inhibits
VEGF-induced endothelial cell function. Blood. 107:931–939. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zimrin AB, Pepper MS, McMahon GA, Nguyen
F, Montesano R and Maciag T: An antisense oligonucleotide to the
notch ligand jagged enhances fibroblast growth factor-induced
angiogenesis in vitro. J Biol Chem. 271:32499–32502. 1996.
View Article : Google Scholar
|
|
21
|
Zhao J, Chen X, Lin W, et al: Total
alkaloids of Rubus aleaefolius Poir inhibit hepatocellular
carcinoma growth in vivo and in vitro via activation
of mitochondrial-dependent apoptosis. Int J Oncol. 42:971–978.
2013.
|
|
22
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other diseases. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar
|
|
24
|
Yancopoulos GD, Davis S, Gale NW, et al:
Vascular-specific growth factors and blood vessel formation.
Nature. 407:242–248. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishiwata I, Sudo T, Kiguchi K and Ishikawa
H: Tumor angiogenesis factors produced by cancer cells. Hum Cell.
12:37–46. 1999.PubMed/NCBI
|
|
26
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jain RK: Tumor angiogenesis and
accessibility: role of vascular endothelial growth factor. Semin
Oncol. 29(6 Suppl 16): 3–9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
therapeutic implications. Semin Oncol. 29(6 Suppl 16): 10–14. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Houck KA, Ferrara N, Winer J, et al: The
vascular endothelial growth factor family: identification of a
fourth molecular species and characterization of alternative
splicing of RNA. Mol Endocrinol. 5:1806–1814. 1991. View Article : Google Scholar : PubMed/NCBI
|
